Covid-19

[Comunicado de imprensa – ainda não publicado] Merck anuncia que o antiviral oral Molnupiravir reduziu o risco de internação ou morte em cerca de 50%, comparado ao placebo, em pacientes com COVID-19 leve ou moderada.

4 Out, 2021 | 10:38h

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Comentários:

Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment – STAT

Covid antiviral pill can halve risk of hospitalization – BBC

Why Merck’s Covid-19 pill molnupiravir could be so important – Vox

‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk – Researchers excited about Merck drug, but caution data are preliminary and price is high – Science

Comentários no Twitter

.@DrEricDing convinced many that stopping the #molnupiravir trial early for benefit was a good idea

But it was NOT

Large body of evidence suggests that stopping early for benefit biases the results: overestimates the benefits of the treatment #EBM https://t.co/b3tHEtliO0 https://t.co/LwuCgqcY0C pic.twitter.com/vyPWc0nd37

— Kari Tikkinen (@KariTikkinen) October 2, 2021

(fio – clique para saber mais)

💡BREAKING—New oral anti-viral drug *molnupiravir* cuts risk of #COVID19 hospitalization and death **in HALF** in a randomized trial. Results so astounding that the trial is being stopped early, and Merck plans to apply for emergency authorization ASAP. 🧵 https://t.co/g8JGNzvuRg pic.twitter.com/K1SwC3QFXS

— Eric Feigl-Ding (@DrEricDing) October 1, 2021

Trombose e trombocitopenia imune induzidas por vacina: resumo da diretriz NICE.

4 Out, 2021 | 10:36h

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance – The BMJ

Diretriz original: NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Conteúdos relacionados:

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

A pandemia arrefecerá até se tornar uma doença comum, como a gripe? O mundo está observando a Dinamarca para ter pistas.

4 Out, 2021 | 10:34h

Will the pandemic fade into an ordinary disease like the flu? The world is watching Denmark for clues – Science

[Preprint] Avaliação do impacto da COVID-19 nos países em desenvolvimento: revisão sistemática, metanálise e implicações de políticas públicas.

4 Out, 2021 | 10:33h

Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications – medRxiv

Comentário no Twitter

Our big new study on the infection fatality rate of COVID-19 in developing countries is out

The news is pretty grim 🧵https://t.co/woX4ijWOQy

— Health Nerd (@GidMK) October 2, 2021